1 / 17

Clinical Investigator’s Program: Why Research Ethics Matter

Clinical Investigator’s Program: Why Research Ethics Matter. Michelle A. Mullen University of Ottawa Departments of Paediatrics & Women’s Studies Bioethicist, CHEO. Clinical Research: an ethical enterprise. Cancer Rx Transplantation Infectious Diseases Cardiovascular Care Genetics.

etoile
Télécharger la présentation

Clinical Investigator’s Program: Why Research Ethics Matter

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Investigator’s Program:Why Research Ethics Matter Michelle A. Mullen University of Ottawa Departments of Paediatrics & Women’s Studies Bioethicist, CHEO

  2. Clinical Research: an ethical enterprise • Cancer Rx • Transplantation • Infectious Diseases • Cardiovascular Care • Genetics

  3. Goals… • Walk in the hall of ignomy • Lessons to be learned? • Why ethics matters… • Good Science & Good Ethics – take home messages

  4. Dr. Roger Poisson 1994 • Falsified data in ground-breaking lumpectomy vs. mastectomy cohort • Claimed he was trying to do the best for his patients: conflated clinician and researcher roles • FDA ban from any access to U.S. funds and disciplined by his professional college

  5. Lessons…? • FDA disqualified Poisson from grants process after he acknowledged falsifying results of other studies • ORI found “115 well-documented instances of data fabrication” • Investigators must continually remember when they are acting as researchers and when they are acting as clinicians. Investigators need adequate training as scientists. • A colleague described Poisson as a “proud man-proud to say that he puts most of his patients in trials, proud to get grants, proud to get his name on research papers”

  6. Dr. Nancy Olivieri 1998 • Dr. Olivieri wanted to tell research subjects and the scientific community of potential (lethal) risks with the drug (deferiprone) that children in a clinical trial were taking as experimental treatment for thalassaemia • The manufacturer of the drug ordered her not to disclose these findings to participants or researchers • Public and protracted conflict

  7. Lessons…? • Institutions need to adopt AND enforce strict conflict of interest polices • Institutions and REBs need to review contracts • Confidentiality clauses that potentially restrict informing either participants or the scientific community are unacceptable (time-limited notification clause) • Clinician investigators need to understand their obligations, rights, responsibilities prior to undertaking clinical research

  8. Mr. Gabriel Lessard • In 1991 Lessard volunteered to take part in a study to screen for prostate cancer • The next year researchers found a slight abnormality but decided the result wasn't important and chose not to tell Lessard • In 1993, researchers did another test, with abnormal results but it was too late, the cancer too invasive

  9. Lessons…? • Quebec coroner Luc Malouin says researchers put medicine on the back seat • "The doctor has the obligation to give the truth to the patient" • Standards for clinical disclosure (Reibl v Hughes SCC) are higher in the research context • Consent, disclosure of pertinent/unexpected findings, disemmination of research results should be considered a priori

  10. Ryan 2002 • 4 year old child died at the Children's Hospital of Eastern Ontario after he was given a "significant overdose" (25X) of an experimental drug (Interleukin II) for ‘treatment’ of NB • CHEO has been praised for its transparent approach in handling this issue

  11. Lessons…? • FDA inspection; letter to trial physician posted on web site • Previous OD and toxicity reported, not taken account of – safety and monitoring • HC did not undertake separate investigation, but notified research centres, drug companies, REBs and hospitals across Canada that adherence with regulations “is obligatory” • Mistakes happen on clinical trials -

  12. Jesse Gelsinger • 18 yo first patient to die in clinical trials for gene therapy • OTC (ornithine transcabamylase) deficiency, usually fatal at birth -some normal cells enabled him to survive with diet / meds • Sept/99 Jesse injected with adenovirus carrying a corrected gene • died four days later (massive immune response with multiple organ failure and brain death)

  13. Lessons…? • FDA concluded scientists involved in the trial broke several rules of conduct: • Inclusion of Gelsinger as a substitute for another volunteer, despite having high ammonia levels that should have led to his exclusion • Failure by the university to report that two patients had experienced serious side effects from the gene therapy • Failure to disclose the deaths of monkeys given a similar treatment in the informed consent documentation. • The University of Pennsylvania later issued a rebuttal, but paid the parents an undisclosed amount in settlement

  14. Why ethics matters… • Why do patients come to us? • Who benefits from clinical research? • Who pays for research? • Starting research process from ethical viewpoint… • Good Science & Good Ethics needed

  15. Good Science & Good Ethics • Equipoise • Roles/dual agency • Disclosure  risks & benefits  conflict of interest  unexpected results  recruitment (vulnerable populations) • Safety & Monitoring • Regulations

  16. Even if I don't finish, we need others to continue. It's got to keep going without me. Terry Fox

More Related